ThinkCyte advances biopharma phenotypic drug discovery programs with publication and presentation milestones

ThinkCyte Inc. Japan France Germany United Kingdom California

at the Society for Laboratory for Automation and Screening (SLAS) meeting in February where ThinkCyte presented how VisionSort was used to perform flow-based high content intracellular phenotypic screening using DNA barcoding technology. In December, the company was also profiled in a special edition of Cell Press highlighting the emerging uses of AI in drug discovery screening.

"Our biopharma customers are looking to integrate new technologies to expand their phenotypic drug screening programs," said Janette Phi, Chief Business Officer at ThinkCyte. "With VisionSort, they can supplement their existing workflows with a fast and flexible new discovery tool that enables them to expand their screening capabilities and build more robust early drug pipelines."

Open access to the publication can be found at https://www.cell.com/cell-reports-methods/fulltext/S2667-2375(24)00062-6,

About ThinkCyte
ThinkCyte, founded in 2016 with offices in Tokyo, Japan and Redwood City, California is a biotechnology company that develops innovative scientific instruments based on integrated, multidisciplinary technologies to enable life science research, diagnostics, and therapeutic development. The company's flagship product, VisionSort, is the world's first AI-based, dual-mode fluorescence and morphometric cell sorting platform and it partners with major global biopharmaceutical companies and leading academic research institutes to further drive groundbreaking research. For more information, please visit www.thinkcyte.com.

To learn more about research partnerships or other partnering opportunities with ThinkCyte, visit https://thinkcyte.com/company/partner or email [e-mail]. To learn more about VisionSort, the commercially available platform powered by Ghost Cytometry, visit https://thinkcyte.com/product/.

View original content:https://www.prnewswire.co.uk/news-releases/thinkcyte-advances-biopharma-phenotypic-drug-discovery-programs-with-publication-and-presentation-milestones-302104291.html